FDA Grants Fast Track Designation to EpicentRx’s RRx-001 for Severe Oral Mucositis Prevention in Head & Neck Cancer Patients
EpicentRx, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001, a novel compound with direct NLRP3 inhibitory and Nrf2 upregulatory effect ...